Toggle light / dark theme

A way of shrinking the devices used in quantum sensing systems has been developed by researchers at the UK Quantum Technology Hub Sensors and Timing, which is led by the University of Birmingham.

Sensing devices have a huge number of industrial uses, from carrying out ground surveys to monitoring volcanoes. Scientists working on ways to improve the capabilities of these sensors are now using quantum technologies, based on , to improve their sensitivity.

Machines developed in laboratories using quantum technology, however, are cumbersome and difficult to transport, making current designs unsuitable for most industrial uses.

Summary: Researchers successfully applied a gene therapy platform to completely correct brain defects in a large animal model of a human genetic disease.

Source: University of Pennsylvania

A lone genetic mutation can cause a life-changing disorder with effects on multiple body systems. Lysosomal storage diseases, for example, of which there are dozens, arise due to single mutations that affect production of critical enzymes required to metabolize large molecules in cells. These disorders affect multiple organs including, notably, the brain, causing intellectual disability of varying degrees.

According to the University of Minnesota trial data supports dexamethasone over Hydroxychloroquine:


Data from a large randomized controlled trial in the United Kingdom showing a benefit from use of the steroid dexamethasone in hospitalized COVID-19 patients was released today in the New England Journal of Medicine (NEJM), while two more studies show no benefit for the malaria drug hydroxychloroquine.

The NEJM data, which were originally reported in a press release in mid-June by the chief investigators of the RECOVERY (Randomized Evaluation of COVID-19 Therapy) trial after an interim analysis, show that in patients needing mechanical ventilation, dexamethasone reduced deaths by 36% compared with usual care. In patients receiving oxygen, the incidence of death was 18% lower for patients on dexamethasone.

“The RECOVERY trial provides evidence that treatment with dexamethasone at a dose of 6 mg once daily for up to 10 days reduces 28-day mortality in patients with Covid-19 who are receiving respiratory support,” investigators with the RECOVERY Collaborative Group, which is led by scientists from the University of Oxford, wrote.